COMBINATION THERAPY FOR TREATING CANCER
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat multiple myeloma or mantle cell lymphoma.
1 . (canceled)
2 . A method for treatment of mantle cell lymphoma comprising administering to a human subject in need thereof:
(a) tazemetostat, or a pharmaceutically acceptable salt thereof, and
(b) one or more second agents selected from lenalidomide, venetoclax, or bendamustine.
3 . (canceled)
4 . The method of claim 2 , wherein the amount of tazemetostat, or a pharmaceutically acceptable salt thereof, administered is between about 100 mg and about 1600 mg, inclusive of the endpoints.
5 . (canceled)
6 . The method of claim 4 , wherein the amount of tazemetostat, or a pharmaceutically acceptable salt thereof, administered is about 800 mg.
7 - 9 . (canceled)
10 . The method of claim 6 , wherein the tazemetostat, or a pharmaceutically acceptable salt thereof, is administered twice per day (BID).
11 . The method of claim 6 , wherein the tazemetostat, or a pharmaceutically acceptable salt thereof, is administered orally.
12 . The method of claim 11 , wherein the tazemetostat, or a pharmaceutically acceptable salt thereof, is administered as a capsule or tablet.
13 . A method of inhibiting or decreasing growth, viability, survival, or proliferation of a mantle cell lymphoma cell comprising contacting the cell with:
(a) tazemetostat or a pharmaceutically acceptable salt thereof, and
(b) one or more second agents selected from lenalidomide, venetoclax, or bendamustine.
14 - 18 . (canceled)
19 . The method of claim 13 , wherein the contacting is in vitro or ex vivo.
20 . The method of claim 13 , wherein the contacting is in vivo by administering the tazemetostat or a pharmaceutically acceptable salt thereof, and the one or more second agents to a human subject harboring the cancer cell.
21 - 74 . (canceled)
75 . The method of claim 12 , wherein the EZH2 inhibitor and the one or more second agents are administered sequentially.
76 . The method of claim 12 , wherein the tazemetostat, or a pharmaceutically acceptable salt thereof, is administered prior to the one or more second agents.
77 . (canceled)
78 . The method of claim 12 , wherein the one or more second agents are administered prior to the tazemetostat, or a pharmaceutically acceptable salt thereof.
79 . The method of claim 2 , wherein the EZH2 inhibitor is a pharmaceutically acceptable salt of tazemetostat.
80 . The method of claim 2 , wherein the second agent is lenalidomide.
81 . The method of claim 2 , wherein the second agent is venetoclax.
82 . The method of claim 2 , wherein the second agent is bendamustine.
83 . The method of claim 13 , wherein the second agent is lenalidomide.
84 . The method of claim 13 , wherein the second agent is venetoclax.
85 . The method of claim 13 , wherein the second agent is bendamustine.